• 1
    Palella FJ, Boyer RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing cause of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006;43:27-43.
  • 2
    Mocroft A, Ledergerber B, Katlama C, et al. Decline in AIDS and death rates in the EuroSIDA study: an observational study. Lancet. 2003;362:22-29.
  • 3
    Patel P, Hanson DL, Sullivan PS, et al. Incidence and types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003. Ann Intern Med. 2008;148:728-736.
  • 4
    Long JL, Engels EA, Moore RD, Gebo KA. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS. 2008;22:489-496.
  • 5
    Collaboration of Observational HIV Epidemiological Research Europe (COHERE) Study Group; Bohlius J, Schmidlin K, Costagliola D, et al. Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting antiretroviral therapy. AIDS. 2009;23:2029-2037.
  • 6
    Spagnuolo V, Galli L, Salpietro S, et al. Ten-year survival among HIV-infected subjects with AIDS- or non-AIDS-defining malignancies. Int J Cancer. 2012;130:2990-2996.
  • 7
    Wang CC, Castillo JJ. Management of HIV-associated lymphomas. Med Health R I. 2011;94:4-6.
  • 8
    Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhedler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol. 2008;26:4834-4842.
  • 9
    Ng AK, Mauch PM. Late effects of Hodgkin's disease and its treatment. Cancer J. 2009;15:164-168.
  • 10
    de Haas EC, Oosting SF, Lefandrt JD, Wolfenbuttel BH, Sleijfer DT, Gietema JA. The metabolic syndrome in cancer survivors. Lancet Oncol. 2010;11:193-203.
  • 11
    Jung HS, Myung SK, Kim BS, Seo HG. Metabolic syndrome in adult cancer survivors. Diabetes Res Clin Pract. 2012;95:275-282.
  • 12
    Guaraldi G, Orlando G, Zona S, et al. Premature age-related comorbidities among HIV-infected persons compared with the general population. Clin Infect Dis. 2011;53:1120-1126.
  • 13
    Deeks SG, Phillips AN. HIV infection, antiretroviral treatment, ageing and non-AIDS related mortality [serial online]. BMJ. 2009;338:a3172.
  • 14
    Simonelli C, Zanussi S, Pratesi C, et al. Immune recovery after autologous stem cell transplantation is not different for HIV-infected versus HIV-uninfected patients with relapsed or refractory lymphoma. Clin Infect Dis. 2010;50:1672-1679.
  • 15
    Bower M, Stebbing J, Tuthill M, et al. Immunological recovery in survivors following chemotherapy for AIDS-related non Hodgkin lymphoma. Blood. 2008;111:3986-3990.
  • 16
    Kaplan JE, Benson C, Holmes KK, et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58(RR-4):1-207, 2009.
  • 17
    Kaplan JE, Masur H, Holmes KK; USPHS; Infectious Disease Society of America. Guidelines for preventing opportunistic infections among HIV-infected persons—2002. Recommendations of the US Public Health Service and the Infectious Diseases Society of America. MMWR Recomm Rep. 2002;51(RR-8):1-52.
  • 18
    The 1999 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus. US Public Health Service (USPHS) and Infectious Diseases Society of America (IDSA). MMWR Recomm Rep. 1999;48(RR-10):1-59, 61-55.
  • 19
    The 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Reccomm Rep. 1992;41(RR-17):1-19.
  • 20
    Adami S, Bertoldo F, Brandi ML, et al. Italian guidelines for the diagnosis, prevention and treatment of osteoporosis [article in Italian]. Reumatismo. 2009;61:1-25.
  • 21
    American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2012;35:S64-S71.
  • 22
    National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis. 2002;39(2 suppl 1):S1-S266.
  • 23
    Bower M, Collins S, Cottrill C, et al. British HIV Association guidelines for HIV-associated malignancies. HIV Med. 2008;9:336-388.
  • 24
    Xicoy B, Ribera JM, Miralles P, et al. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage of immunodeficiency related Hodgkin lymphoma. Haematologica. 2007;92:191-198.
  • 25
    Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, Adriamycin, vincristine, prednisone and rituximab in patients with HIV-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411-419.
  • 26
    Oriol A, Ribera JM, Bergual J, et al. High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma cancer: comparisons of results in human immunodeficiency virus-infected and non infected patients. Cancer. 2008;113:117-125.
  • 27
    Ferreri AJ, Bruno Ventre M, Donadoni G, et al. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt's lymphoma. Br J Haematol. 2012;159:252-255.
  • 28
    Gisselbrech C, Glass B, Mounier N, et al. Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol. 2010;28:4184-4190.
  • 29
    Montoto S, Wilson J, Shaw K, et al. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma. AIDS. 2010;24:851-856.
  • 30
    Powles T, Imami N, Nelson M, Gazzard BG, Bower M. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS. 2002;16:531-536.
  • 31
    Resino S, Perez A, Seoane E, et al. Immune reconstitution after autologous peripheral blood stem cell transplantation in HIV-infected patients: might be better than expected? AIDS Res Hum Retroviruses. 2007;23:543-548.
  • 32
    Simonelli C, Zanussi S, Cinelli R, et al. Impact of concomitant antiblastic chemotherapy on human immunodeficiency virus (HIV) viremia and genotyping in HIV-infected patients with non-Hodgkin lymphoma. Clin Infect Dis. 2003;37:820-827.
  • 33
    Sparano JA, Hu X, Wiernik PH, et al. Opportunistic infection and immunological function in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma treated with chemotherapy. J Natl Cancer Inst. 1997;89:301-307.
  • 34
    Alfa-Wali M, Tait D, Allen-Mersh T, et al. Colorectal cancer in HIV positive individuals: the immunological effects of the treatment. Eur J Cancer. 2011;47:2403-2407.
  • 35
    Hengee UR, Esser S, Rudel HP, Goos M. Long-term chemotherapy of HIV-associated Kaposi's sarcoma with liposomal doxorubicin. Eur J Cancer. 2001;37:878-883.
  • 36
    Thompson CA, Mauck K, Havyer R, Bhagra A, Kalsi H, Hayes SN. Care of the adult Hodgkin lymphoma survivors. Am J Med. 2011;124:1106-1112.
  • 37
    Lang S, Mary-Krause M, Simon A, et al. HIV replication and immune status are independent predictors of the risk of myocardial infarction in HIV-infected individuals. Clin Infect Dis. 2012;55:600-607.
  • 38
    Mc Comsey GA, Tebas P, Shane E, et al. Bone disease in HIV-infection: a practical review and recommendation for HIV care providers. Clin Infect Dis. 2010;51:937-946.
  • 39
    Galli L, Salpietro S, Pellicciotta G, et al. Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. Eur J Epidemiol. 2012;27:657-665.
  • 40
    Guiguet M, Boue F, Cadranel J, Lang JM, Rosenthal E, Costagliola D; Clinical Epidemiology Group of the FHDH-ANRS CO4 Cohort. Effect of immunodeficiency, HIV viral load and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a perspective cohort study. Lancet Oncol. 2009;10:1152-1161.
  • 41
    Biggar RJ, Jaffe ES, Goedert JJ, Chaturvedi A, Pfeiffer R, Engels EA. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood. 2006;108:3786-3791.